ProfileGDS5678 / 1448914_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 64% 70% 68% 64% 75% 64% 67% 66% 70% 67% 67% 69% 67% 67% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.8452264
GSM967853U87-EV human glioblastoma xenograft - Control 24.3836770
GSM967854U87-EV human glioblastoma xenograft - Control 34.1325268
GSM967855U87-EV human glioblastoma xenograft - Control 43.817964
GSM967856U87-EV human glioblastoma xenograft - Control 55.0185875
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.8706164
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.101767
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.9992666
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.3753870
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.0835867
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.0263367
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.2404869
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.0811767
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.0809867